A multilateral effort to develop DNA vaccines against falciparum malaria

Trends in Parasitology

Volumn 18, Issue 3, 2002, Pages 129-135

  Kumar, Sanjai ^a   Epstein, Judith E ^a   Richie, Thomas L ^a   Nkrumah, Francis K ^b   Soisson, Lorraine ^c   Carucci, Daniel J ^a   Hoffman, Stephen L ^d  

^a NAVAL MEDICAL RESEARCH CENTER   (United States)

^b University of Ghana   (Ghana)

^c UNITED STATES AGENCY FOR INTERNATIONAL DEVELOPMENT   (United States)

^d CELERA GENOMICS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APICAL MEMBRANE ANTIGEN 1; B7 ANTIGEN; CD40 LIGAND; CIRCUMSPOROZOITE PROTEIN; DNA VACCINE; ERYTHROCYTE BINDING PROTEIN 175; EXPORTED PROTEIN 1; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN; INTERLEUKIN 12; INTERLEUKIN 2; LIVER STAGE ANTIGEN 1; LIVER STAGE ANTIGEN 3; LIVER STAGE PARASITE; MALARIA VACCINE; MEROZOITE SURFACE PROTEIN 1; MEROZOITE SURFACE PROTEIN 2; MEROZOITE SURFACE PROTEIN 3; MEROZOITE SURFACE PROTEIN 4; MEROZOITE SURFACE PROTEIN 5; PARASITE ANTIGEN; RHOPTRY ASSOCIATED PROTEIN; SERINE REPEAT ANTIGEN; SPOROZOITE SURFACE PROTEIN 2; UNCLASSIFIED DRUG;

CLINICAL TRIAL; CODON; DNA TRANSCRIPTION; DRUG DESIGN; DRUG EFFECT; DRUG SAFETY; DRUG TOLERANCE; ERYTHROCYTE; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; MALARIA FALCIPARUM; NONHUMAN; PARASITEMIA; PLASMID; PLASMODIUM FALCIPARUM; REVIEW; T LYMPHOCYTE; TECHNOLOGY; VACCINATION;

ANIMALS; HUMANS; INTERNATIONAL COOPERATION; MALARIA VACCINES; MALARIA, FALCIPARUM; PLASMODIUM FALCIPARUM; VACCINES, DNA;

PLASMODIUM FALCIPARUM; PROTOZOA;

EID: 0036498381     PISSN: 14714922     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1471-4922(01)02207-3     Document Type: Review

References (55)

1. Transmission blocking vaccines: Uses and current status of development
2. Protection of humans against malaria by immunization with radiation attenuated Plasmodium sp. Sporozoites
3. Gamma globulin and acquired immunity to human malaria
4. Mechanisms underlying the monocyte-mediated antibody dependent killing of Plasmodium falciparum asexual blood stages
5. Impact of permethrin impregnated bednets on child mortality in Kassena-Nankana district, Ghana: A randomized controlled trial
6. Widespread distribution of insecticide-impregnated curtains reduces child mortality, prevalence and intensity of malaria infection, and malaria transmission in rural Burkina Faso
7. Protection of mice against Plasmodium yoelii sporozoite challenge with P. yoelii merozoite surface protein 1 DNA vaccines
8. Immunogenicity and efficacy in Aotus monkeys of four recombinant Plasmodium falciparum vaccines in multiple adjuvant formulations based on the 19-kilodalton C terminus of merozoite surface protein 1
9. Protection of Aotus monkeys by Plasmodium falciparum EBA-175 region II DNA prime-protein boost immunization regimen
10. + T cells and antibodies required for immunity to malaria sporozoites
11. + T cells (cytotoxic/suppressors) are required for protection in mice immunized with malaria sporozoites
12. Cloned cytotoxic T cells recognize an epitope in the circumsporozoite protein and protect against malaria
13. + cytolytic T cell clones derived against the Plasmodium yoelii circumsporozoite protein protect against malaria
14. A T cell clone directed at the circumsporozoite protein which protects mice against both Plasmodium yoelii and Plasmodium berghei
15. Protection against malaria by immunization with plasmid DNA encoding circumsporozoite protein
16. + T cells
17. + T cells in the Plasmodium yoelii model
18. The complexity of protective immunity against liver-stage malaria
19. Circumsporozoite proteins of human malaria parasites Plasmodium falciparum and Plasmodium vivax
20. Monovalent fragments (Fab) of monoclonal antibodies to a sporozoite surface antigen (Pb44) protect mice against malarial infection
21. Inability of malaria vaccine to induce antibodies to a protective epitope within its sequences
22. Degenerate cytotoxic T cell epitopes from P. falciparum restricted by multiple HLA-A and HLA-B supertype alleles
23. + cell-, interferon gamma-, and nitric oxide-dependent immunity
24. Protection against malaria by vaccination with sporozoite surface protein 2 plus CS protein
25. Preventing merozoite invasion of erythrocytes
26. Vaccines
27. Immune responses in malaria
28. Host age as a determinant of naturally acquired immunity to Plasmodium falciparum
29. Immunity to non-cerebral severe malaria is acquired after one or two infections
30. Malaria vaccine
31. Simultaneous induction of multiple antigen-specific cytotoxic T lymphocytes in nonhuman primates by immunization with a mixture of four Plasmodium falciparum DNA plasmids
32. A DNA vaccine encoding the 42 kD C-terminus of merozoite surface protein 1 of Plasmodium falciparum induces antibody, interferon-γ and cytotoxic T cell responses in rhesus monkeys: Immuno-stimulatory effects of granulocyte macrophage-colony stimulating factor
33. Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine
34. Malaria DNA vaccines in Aotus monkeys
35. Safety, tolerability and humoral immune responses after intramuscular administration of a malaria DNA vaccine to healthy adult volunteers
36. + type 1 responses in humans by a malaria DNA vaccine
37. Codon usage and tRNA content in unicellular and multicellular organisms
38. The codon Adaptation Index - A measure of directional synonymous codon usage bias and its potential applications
39. Codon usage in bacteria; correlation with gene expressivity
40. Codon Selection in yeast
41. An evolutionary perspective on synonymous codon usage in unicellular organisms
42. Increased expression and immunogenicity of sequence-modified human immunodeficiency virus type 1 gag gene
43. Codon optimization effect on translational efficiency of DNA vaccine in mammalian cells: Analysis of plasmid DNA encoding a CTL epitope derived from microorganisms
44. Codon optimization of gene fragments encoding Plasmodium falciparum enhances DNA vaccine protein expression and immunogenicity in mice
45. In vivo engineering of a cellular immune response by coadministration of IL-12 expression vector with a DNA immunogen
46. TCR vaccines for active immunotherapy of T cell malignancies
47. A plasmid encoding murine granulocyte-macrophage colony-stimulating factor increases protection conferred by a malaria DNA vaccine
48. Improving protective immunity induced by DNA-based immunization: Priming with antigen and GM-CSF-encoding plasmid DNA and boosting with antigen-expressing recombinant poxvirus
49. Prevention of neonatal tolerance by a plasmid encoding GM-CSF
50. + T cell induction and complete protective efficacy of malaria DNA vaccination followed by boosting with modified vaccinia virus Ankara strain
51. Enhanced T-cell immunogenicity and protective efficacy of a human immunodeficiency virus type 1 vaccine regimen consisting of consecutive priming with DNA and boosting with recombinant fowlpox virus
52. Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant poxvirus booster immunizations
53. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine
54. Absence of antigenic competition in Aotus monkeys immunized with Plasmodium falciparum DNA vaccines delivered as a mixture
55. African children with malaria in an area of intense Plasmodium falciparum transmission: Features on admission to the hospital and risk factors for death